Quick Answer
Neurogene Inc. reported R&D Expense of $75.01 million for fiscal year 2025.
Neurogene Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $75.01M | +23.1% |
| 2024 | $60.92M | +37.2% |
| 2023 | $44.39M | -6.5% |
| 2022 | $47.51M | +21.3% |
| 2021 | $39.16M | -6.3% |
| 2018 | $41.79M | +15.2% |
| 2017 | $36.27M | +27.8% |
| 2016 | $28.38M | +79.6% |
| 2015 | $15.80M | -12.6% |
| 2014 | $18.08M | +137.9% |
| 2013 | $7.60M | +25.7% |
| 2012 | $6.05M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.24M | +5.9% | -11.0% |
| June 30, 2025 | $19.37M | +23.0% | +9.0% |
| March 31, 2025 | $17.76M | +31.2% | +9.1% |
| September 30, 2024 | $16.29M | +40.3% | +3.4% |
| June 30, 2024 | $15.74M | +52.5% | +16.3% |
| March 31, 2024 | $13.54M | +31.7% | +16.7% |
| September 30, 2023 | $11.61M | +22.5% | +12.5% |
| June 30, 2023 | $10.32M | -5.8% | +0.4% |
- Neurogene Inc. showed an increase of +23.1% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, Neurogene Inc.’s r&d expense has grown by 1140.8% (from $6.05 million to $75.01 million).
- The most recent figure is from Neurogene Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: